Division of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
Endocr Relat Cancer. 2011 Jun 8;18(3):371-84. doi: 10.1530/ERC-11-0057. Print 2011 Jun.
The mechanisms underlying the association of menopausal hormone therapy (MHT) with reduced colorectal cancer (CRC) risk are unknown and the identification of genetic modifiers may yield further insight. We explored the effect modification of MHT-associated CRC risk in postmenopausal women by 47 polymorphisms with known or putative functional relevance in 16 candidate genes related to hormone metabolism (COMT, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP17A1, GSTP, and HSD17B1), transport (ABCB1), and signaling (ESR1, ESR2, SHBG, PGR, and NR1I2). A total of 685 CRC patients and 684 healthy controls from a German population-based case-control study (DACHS) were genotyped. Multiplicative statistical interaction between polymorphisms and ever MHT use as well as duration of use was assessed using multivariate logistic regression. CRC risk associated with ever MHT use as well as with duration was significantly modified by rs1202168 in the transporter gene ABCB1 (P interaction=0.04). The MHT-associated risk reduction was not significant in homozygous non-carriers (odds ratio (OR) ever use=0.84, 95% confidence interval (CI) 0.53-1.34; OR per 5 year duration=0.94, 95% CI 0.83-1.08), while homozygous carriers of the minor T allele had a 57% lower risk with ever use of MHT (95% CI 0.21-0.88) and a 22% lower risk per 5 years of MHT use (95% CI 0.62-0.97). Significant effect modification was also observed for the ESR1_rs910416 polymorphism (P interaction=0.03 for ever use and 0.07 for duration of use), whereby the decreased risk was attenuated in homozygous carriers of the minor C allele (OR ever use=0.87, 95% CI 0.48-1.60, OR per 5 year duration=0.99, 95% CI 0.83-1.18). Results of this exploratory study provide first evidence that polymorphisms in genes related to estrogen transport and signaling may modify MHT-associated CRC risk but warrant replication in an independent population.
绝经后激素治疗(MHT)与降低结直肠癌(CRC)风险相关的机制尚不清楚,而鉴定遗传修饰因子可能会提供进一步的见解。我们通过 16 个与激素代谢(COMT、CYP1A1、CYP1A2、CYP1B1、CYP2C9、CYP2C19、CYP3A4、CYP17A1、GSTP 和 HSD17B1)、转运(ABCB1)和信号(ESR1、ESR2、SHBG、PGR 和 NR1I2)相关的候选基因中的 47 个具有已知或假定功能相关性的多态性,探讨了 MHT 相关 CRC 风险在绝经后妇女中的效应修饰作用。来自德国基于人群的病例对照研究(DACHS)的 685 名 CRC 患者和 684 名健康对照者进行了基因分型。使用多元逻辑回归评估多态性与既往 MHT 使用以及使用时间的乘积统计交互作用。与既往 MHT 使用相关的 CRC 风险以及与使用时间相关的 CRC 风险显著受转运基因 ABCB1 中的 rs1202168 影响(P 交互作用=0.04)。在同型纯合非携带者中,MHT 相关的风险降低不显著(使用时的比值比(OR)=0.84,95%置信区间(CI)0.53-1.34;每 5 年使用的 OR=0.94,95%CI 0.83-1.08),而小 T 等位基因的同型纯合携带者使用 MHT 的风险降低 57%(95%CI 0.21-0.88),每 5 年使用 MHT 的风险降低 22%(95%CI 0.62-0.97)。ESR1_rs910416 多态性也观察到了显著的效应修饰作用(P 交互作用=0.03 用于使用,P 交互作用=0.07 用于使用时间),小 C 等位基因的同型纯合携带者的风险降低作用减弱(OR 使用时=0.87,95%CI 0.48-1.60,OR 每 5 年使用一次=0.99,95%CI 0.83-1.18)。这项探索性研究的结果首次提供证据表明,与雌激素转运和信号相关的基因中的多态性可能会改变 MHT 相关的 CRC 风险,但需要在独立人群中进行复制。